🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06023784
Recruiting Not applicable

The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block

NCT06023784 · tracked via the Priya Life Science China tracker
Sponsor
Peking Union Medical College Hospital
Phase
Not applicable
Started
2023-09-30
Last updated
2026-09-21

Condition(s) studied

Left Bundle Branch Area PacingRight Ventricular PacingAtrioventricular BlockAtrial Fibrillation

Investigational drug(s) / intervention(s)

left bundle branch area pacingright ventricular pacing

left bundle branch area pacing: Left bundle branch area pacing(LBBAP) is a novel physiological pacing form for ventricular pacing. In patients received LBBAP, the pacing lead will be placed at left bundle branch area to achieve narrow paced QRS duration.

right ventricular pacing: Right ventricular pacing is the traditional pacing modality for ventricular pacing. The pacing lead was placed in the apex or septum of right ventricle.

Study summary

This is a single-center, randomized controlled study. The aim of this study is to compare the impact of left bundle branch area pacing versus traditional right ventricular pacing on the incidence of atrial fibrillation in patients with atrioventricular block.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * Adult patients aged 18-85; * AV block patients with ventricular pacing indications and the expected rate of ventricular pacing(VP)\> 40%, including (a) third-degree AV block; (b) second degree AV block (type II); (c) intermittent advanced AV block with expected VP\>40%; (d) symptomatic first degree AV block and PR interval on ECG \> 300ms; * Signed informed consent; Exclusion Criteria: * Baseline echocardiographic assessment of patients with impaired LV function (LVEF\<50%); * Patients with the history of atrial fibrillation; * Having difficulties in follow-up: Those who cannot accept 2-year follow-up on time due to physical condition or other reasons; * Pacemaker replacement without new implanted ventricular electrodes; * Surgery is required within 1 year due to severe structural heart disease; * Patients with tricuspid mechanical valve replacement, or congenital heart disease (including transposition of the great arteries, or permanent left superior vena cava, etc); * AV block resulting from: (a) Hypertrophic cardiomyopathy(HCM), (b) ventricular septal defect repair, and those who are unlikely to achieve successful LBBAP procedure.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital Beijing Beijing Municipality Recruiting

More Peking Union Medical College Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06023784 on ClinicalTrials.gov ↗ ← All trials in China